Characteristics of the patients before the second TFR attempt
| Patient characteristics . | Patients accepting a TFR2, n = 32 . | Patients not accepting a TFR2, n = 33 . |
|---|---|---|
| Demography | ||
| Age, median (range), y, NS | 47.6 (18.9-77.5) | 51.3 (33.5-80.2) |
| Sex ratio (M/F) | 0.43 | 0.47 |
| Disease characteristics | ||
| Sokal score %, low/intermediate/high, NS | 44/28/28 | 55/30/15 |
| CML duration before TFR1, median, y, NS | 10.25 | 8.05 |
| Therapy before TFR1 | ||
| TKI duration, median (range), y, NS | 6 (2.2-12.5) | 7.9 (2.2-16) |
| Therapy before TFR2 | ||
| TKI duration post-TFR1, median (range), y | 3.4 (2.2-12.5) | |
| Total TKI duration (pre- and post-TFR1), median (range), y | 9.5 (5-15.6) | |
| TKI post-TFR1 | ||
| Imatinib, n (%) | 16 (50) | |
| 2G TKI, n (%) | 16 (50) | |
| Imatinib duration from end TFR1, median, y | 3.1 | |
| 2G TKI duration from end TFR1, median, y | 3.2 | |
| Response before TFR2 | ||
| MR4, % | 100 | |
| MR4 duration, median (range), y | 2.3 (0.8-5.8) | |
| Stable MR4, % | 100 | |
| MR4.5, % | 94 | |
| MR4.5 duration, median (range), y | 2.3 (0.6-5.6) | |
| Stable MR4.5, % | 66 |
| Patient characteristics . | Patients accepting a TFR2, n = 32 . | Patients not accepting a TFR2, n = 33 . |
|---|---|---|
| Demography | ||
| Age, median (range), y, NS | 47.6 (18.9-77.5) | 51.3 (33.5-80.2) |
| Sex ratio (M/F) | 0.43 | 0.47 |
| Disease characteristics | ||
| Sokal score %, low/intermediate/high, NS | 44/28/28 | 55/30/15 |
| CML duration before TFR1, median, y, NS | 10.25 | 8.05 |
| Therapy before TFR1 | ||
| TKI duration, median (range), y, NS | 6 (2.2-12.5) | 7.9 (2.2-16) |
| Therapy before TFR2 | ||
| TKI duration post-TFR1, median (range), y | 3.4 (2.2-12.5) | |
| Total TKI duration (pre- and post-TFR1), median (range), y | 9.5 (5-15.6) | |
| TKI post-TFR1 | ||
| Imatinib, n (%) | 16 (50) | |
| 2G TKI, n (%) | 16 (50) | |
| Imatinib duration from end TFR1, median, y | 3.1 | |
| 2G TKI duration from end TFR1, median, y | 3.2 | |
| Response before TFR2 | ||
| MR4, % | 100 | |
| MR4 duration, median (range), y | 2.3 (0.8-5.8) | |
| Stable MR4, % | 100 | |
| MR4.5, % | 94 | |
| MR4.5 duration, median (range), y | 2.3 (0.6-5.6) | |
| Stable MR4.5, % | 66 |
NS, nonsignificant; TFR2, second attempt of treatment-free remission.